[Treatment of giant cell arteritis].

Traitement de l’artérite à cellules géantes.
Abatacept / therapeutic use Anti-Inflammatory Agents, Non-Steroidal / therapeutic use Antibodies, Monoclonal, Humanized / therapeutic use Aspirin / therapeutic use Azathioprine / therapeutic use Drug Administration Schedule Giant Cell Arteritis / complications Glucocorticoids / administration & dosage Humans Immunosuppressive Agents / therapeutic use Leflunomide / therapeutic use Methotrexate / therapeutic use Prednisone / therapeutic use Ustekinumab / therapeutic use

Journal

Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 16 03 2019
accepted: 11 06 2019
pubmed: 22 7 2019
medline: 18 10 2019
entrez: 21 7 2019
Statut: ppublish

Résumé

Glucocorticoids (GC) remain the gold standard of the treatment of giant cell arteritis provided objectives of GC-tapering are accurately followed: 15 to 20mg/day at 3 months, 10mg/day at 6 months, 5mg/day at 9-12 months and withdrawal between 12 and 18 months. In case of corticodependance at ≥7.5 mg/day of prednisone or intolerance to GC, a GCsparing therapy has to be introduced, mainly methotrexate or tocilizumab. Individual characteristics of each patient, data about the efficacy of the treatment, its cost and how easy the follow-up under this treatment is are important factors to consider for choosing the right GC-sparing therapy. For all these reasons, except particular situations, we prefer using methotrexate before tocilizumab. Prevention of cardiovascular events is an important aspect of the treatment of GCA. We recommend using aspirin (75-100mg/day) during the first month of treatment or longer in case of occurrence of an ischemic complication. Each patient treated for GCA should receive a prevention of osteoporosis with respect of usual recommendations.

Identifiants

DOI: 10.1016/j.lpm.2019.06.002 PMID: 31324351
pubmed: 31324351
pii: S0755-4982(19)30284-2
doi: 10.1016/j.lpm.2019.06.002
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Antibodies, Monoclonal, Humanized 0
Glucocorticoids 0
Immunosuppressive Agents 0
Abatacept 7D0YB67S97
Ustekinumab FU77B4U5Z0
Leflunomide G162GK9U4W
tocilizumab I031V2H011
Azathioprine MRK240IY2L
Aspirin R16CO5Y76E
Prednisone VB0R961HZT
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

968-979

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Maxime Samson (M)

CHU Dijon Bourgogne, hôpital François-Mitterrand, service de médecine interne et immunologie clinique, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France; Université Bourgogne-Franche Comté, Inserm, EFS BFC, UMR1098, 21000 Dijon, France. Electronic address: maxime.samson@chu-dijon.fr.

Hélène Greigert (H)

CHU Dijon Bourgogne, hôpital François-Mitterrand, service de médecine interne et immunologie clinique, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France; Université Bourgogne-Franche Comté, Inserm, EFS BFC, UMR1098, 21000 Dijon, France.

Thibault Ghesquière (T)

CHU Dijon Bourgogne, hôpital François-Mitterrand, service de médecine interne et immunologie clinique, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France; Université Bourgogne-Franche Comté, Inserm, EFS BFC, UMR1098, 21000 Dijon, France.

Bernard Bonnotte (B)

CHU Dijon Bourgogne, hôpital François-Mitterrand, service de médecine interne et immunologie clinique, 2, boulevard Mal-de-Lattre-de-Tassigny, 21000 Dijon, France; Université Bourgogne-Franche Comté, Inserm, EFS BFC, UMR1098, 21000 Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Abatacept › [Treatment of giant cell arteritis].
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Anti-inflammatoires non stéroïdiens › [Treatment of giant cell arteritis].
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › [Treatment of giant cell arteritis].
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Hydroxybenzoates › Salicylates › Acide acétylsalicylique › [Treatment of giant cell arteritis].
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Thionucléosides › Azathioprine › [Treatment of giant cell arteritis].
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Calendrier d'administration des médicaments › [Treatment of giant cell arteritis].
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Vascularite du système nerveux central › Artérite à cellules géantes › [Treatment of giant cell arteritis].
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Glucocorticoïdes › [Treatment of giant cell arteritis].
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [Treatment of giant cell arteritis].
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › [Treatment of giant cell arteritis].
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Isoxazoles › Léflunomide › [Treatment of giant cell arteritis].
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Ptéridines › Aminoptérine › Méthotrexate › [Treatment of giant cell arteritis].
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Prégnanes › Prégnadiènes › Prégnadiènediols › Prednisone › [Treatment of giant cell arteritis].
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Ustékinumab › [Treatment of giant cell arteritis].